M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia. Shen W, Plotkin JL, Francardo V, Ko WK, Xie Z, Li Q, Fieblinger T, Wess J, Neubig RR, Lindsley CW, Conn PJ, Greengard P, Bezard E, Cenci MA, Surmeier DJ (2015) Neuron 88: 762-73 Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. Cheng HF, Becker BN, Harris RC (1996) J Clin Invest 97: 2745-52 Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease. Ahmed MR, Berthet A, Bychkov E, Porras G, Li Q, Bioulac BH, Carl YT, Bloch B, Kook S, Aubert I, Dovero S, Doudnikoff E, Gurevich VV, Gurevich EV, Bezard E (2010) Sci Transl Med 2: 28ra28 Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia. Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA (2011) Brain 134: 2339-57 6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons. Cole DG, Kobierski LA, Konradi C, Hyman SE (1994) Proc Natl Acad Sci U S A 91: 9631-5 Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesia. Naydenov AV, Vassoler F, Luksik AS, Kaczmarska J, Konradi C (2010) Acta Neuropathol 120: 623-31 The thorny problem of dyskinesias: dendritic spines, synaptic plasticity, and striatal dysfunction. Deutch AY (2014) Biol Psychiatry 75: 676-7 Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Biol Psychiatry 62: 800-10 cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum. Andersson M, Konradi C, Cenci MA (2001) J Neurosci 21: 9930-43 Dopamine receptor antagonism by the novel antianxiety drug, buspirone. McMillen BA, Matthews RT, Sanghera MK, Shepard PD, German DC (1983) J Neurosci 3: 733-8 Transcriptome analysis in a rat model of L-DOPA-induced dyskinesia. Konradi C, Westin JE, Carta M, Eaton ME, Kuter K, Dekundy A, Lundblad M, Cenci MA (2004) Neurobiol Dis 17: 219-36 L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain. Bezard E, Gross CE, Qin L, Gurevich VV, Benovic JL, Gurevich EV (2005) Neurobiol Dis 18: 323-35 Molecular profiling of experimental Parkinson's disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. Pierson J, Norris JL, Aerni HR, Svenningsson P, Caprioli RM, Andrén PE (2004) J Proteome Res 3: 289-95 Dopamine synthesis and D3 receptor activation in pancreatic β-cells regulates insulin secretion and intracellular [Ca(2+)] oscillations. Ustione A, Piston DW (2012) Mol Endocrinol 26: 1928-40 Minireview: Dopaminergic regulation of insulin secretion from the pancreatic islet. Ustione A, Piston DW, Harris PE (2013) Mol Endocrinol 27: 1198-207 Functional MRI of basal ganglia responsiveness to levodopa in parkinsonian rhesus monkeys. Chen Q, Andersen AH, Zhang Z, Ovadia A, Cass WA, Gash DM, Avison MJ (1999) Exp Neurol 158: 63-75 Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Cenci MA, Konradi C (2010) Prog Brain Res 183: 209-33 5-HT2A receptor antagonists improve motor impairments in the MPTP mouse model of Parkinson's disease. Ferguson MC, Nayyar T, Deutch AY, Ansah TA (2010) Neuropharmacology 59: 31-6 Pharmacological stimulation of metabotropic glutamate receptor type 4 in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia: Comparison between a positive allosteric modulator and an orthosteric agonist. Iderberg H, Maslava N, Thompson AD, Bubser M, Niswender CM, Hopkins CR, Lindsley CW, Conn PJ, Jones CK, Cenci MA (2015) Neuropharmacology 95: 121-9 Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment. Ahmed MR, Bychkov E, Gurevich VV, Benovic JL, Gurevich EV (2008) J Neurochem 104: 1622-36 The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. Jones CK, Bubser M, Thompson AD, Dickerson JW, Turle-Lorenzo N, Amalric M, Blobaum AL, Bridges TM, Morrison RD, Jadhav S, Engers DW, Italiano K, Bode J, Daniels JS, Lindsley CW, Hopkins CR, Conn PJ, Niswender CM (2012) J Pharmacol Exp Ther 340: 404-21 Dopamine biosynthesis is selectively abolished in substantia nigra/ventral tegmental area but not in hypothalamic neurons in mice with targeted disruption of the Nurr1 gene. Castillo SO, Baffi JS, Palkovits M, Goldstein DS, Kopin IJ, Witta J, Magnuson MA, Nikodem VM (1998) Mol Cell Neurosci 11: 36-46 Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism. Brown AM, Deutch AY, Colbran RJ (2005) Eur J Neurosci 22: 247-56 Induced ovulation in aged female rats by L-dopa implants into the medial preoptic area. Cooper RL, Brandt SJ, Linnoila M, Walker RF (1979) Neuroendocrinology 28: 234-40 Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E (2005) Parkinsonism Relat Disord 11 Suppl 1: S25-9 Validating an objective video-based dyskinesia severity score in Parkinson's disease patients. Rao AS, Dawant BM, Bodenheimer RE, Li R, Fang J, Phibbs F, Hedera P, Davis T (2013) Parkinsonism Relat Disord 19: 232-7 GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson's disease via its RGS homology domain. Ahmed MR, Bychkov E, Li L, Gurevich VV, Gurevich EV (2015) Sci Rep 5: 10920 Acceleration of HIV dementia with methamphetamine and cocaine. Nath A, Maragos WF, Avison MJ, Schmitt FA, Berger JR (2001) J Neurovirol 7: 66-71 Principal component analysis of the dynamic response measured by fMRI: a generalized linear systems framework. Andersen AH, Gash DM, Avison MJ (1999) Magn Reson Imaging 17: 795-815 Mapping drug-induced changes in cerebral R2* by Multiple Gradient Recalled Echo functional MRI. Chen Q, Andersen AH, Zhang Z, Ovadia A, Gash DM, Avison MJ (1996) Magn Reson Imaging 14: 469-76 Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. Maller A, Hyland K, Milstien S, Biaggioni I, Butler IJ (1997) J Child Neurol 12: 349-54
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.